REVMAN_ID,REVIEW_TITLE,PERFBIAS_RISK,PERFBIAS_JUDGEMENT,YEAR
STD-Akhondzadeh-2008,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Identical appearing tablets were used[comma] effectiveness of this method was not mentioned.,2008
STD-Buchanan-2008,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2008
STD-Caroff-2007,Acetylcholinesterase inhibitors for schizophrenia,Unclear Risk,No information available.,2007
STD-Chouinard-2007,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2007
STD-Dyer-2008,Acetylcholinesterase inhibitors for schizophrenia,Unclear Risk,No information available.,2008
STD-Fagerlund-2007,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2007
STD-Freudenreich-2005,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Identical appearing tablets were used[comma] effectiveness of this method was not mentioned.,2005
STD-Friedman-2002c,Acetylcholinesterase inhibitors for schizophrenia,Unclear Risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2002
STD-Keefe-2008a,Acetylcholinesterase inhibitors for schizophrenia,Unclear Risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2008
STD-Kim-2005b,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2005
STD-Kohler-2007,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2007
STD-Lee-2005,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2005
STD-Nahas-2003,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2003
STD-Schubert-2006,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2006
STD-Sharma-2006,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2006
STD-Tugal-2003,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2003
STD-Tuma-2003,Acetylcholinesterase inhibitors for schizophrenia,Low risk,Both the participants and investigators were blinded to the intervention. Effectiveness of this method was not mentioned.,2003
STD-acupoint-cat---Sun-2005,Acupuncture for schizophrenia,High risk,Not used sham acupoint catgut treatment.,2005
STD-acupoint-cat---Wang-1997,Acupuncture for schizophrenia,Unclear Risk,Not used; sham acupoint catgut treatment.,1997
STD-acupoint-inj---Pan-2002,Acupuncture for schizophrenia,High risk,Sham acupoint injection not used.,2002
STD-acupoint-inj---Wang-2000,Acupuncture for schizophrenia,High risk,Sham acupoint injection not used.,2000
STD-acupoint-inj---Yang-2000,Acupuncture for schizophrenia,High risk,Sham acupoint injection not used.,2000
STD-EACT---Xue-1987,Acupuncture for schizophrenia,High risk,Author compared two groups and used electrodes with different positions.,1987
STD-electro---Chen-2006,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2006
STD-electro---Chen-2008,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2008
STD-electro---Cheng-2009,Acupuncture for schizophrenia,Low risk,Report stated - "blinded to the treatment allocation"; the acupuncturist was "instructed not to communicate with the patients and the clinical investigators"; the participants were "acupuncture-naive patients" and "there was also limited contact between the study participants and restricted conversation between acupuncturist and participants during treatment".,2009
STD-electro---Cui-2000,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2000
STD-electro---Ding-2005,Acupuncture for schizophrenia,High risk,Not used sham electroacupuncture and doctors often told patients (electroacupuncture + antipsychotics group) the importance and treatment mechanism of acupuncture.,2005
STD-electro---Wang-2005,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2005
STD-electro---Xiong-2010,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2010
STD-electro---Yao-2006,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2006
STD-electro---Zhang-1987,Acupuncture for schizophrenia,High risk,Sham electroacupuncture or any other dummy treatments not used.,1987
STD-electro---Zhang-1993,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,1993
STD-electro---Zhang-2001,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2001
STD-electro---Zhou-1997,Acupuncture for schizophrenia,High risk,Author compared two groups and did not use sham electroacupuncture.,1997
STD-laser---Liu-1986,Acupuncture for schizophrenia,High risk,Author reported that three groups all used laser irradiation (two real and one sham) and one group combined with chlorpromazine but did not reported the other two groups used dummy drug.,1986
STD-laser---Ma-1999,Acupuncture for schizophrenia,Unclear Risk,Sham laser irradiation not used.,1999
STD-laser---Zhang-1991,Acupuncture for schizophrenia,High risk,Though author compared 3 groups and used sham laser acupuncture did not use dummy medications.,1991
STD-traditional---Bouhlel-2011,Acupuncture for schizophrenia,Low risk,Reports stated - "double-blind". The author reported that both the patient and the psychiatrist did not know if it was a true traditional acupuncture treatment or a placebo (sham acupuncture).,2011
STD-traditional---Liu-2010,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2010
STD-traditional---Luo-2006,Acupuncture for schizophrenia,Unclear Risk,Report stated - "using single-blind method". No further details.,2006
STD-traditional---Ma-2008,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2008
STD-traditional---Tang-2005,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2005
STD-traditional---Wang-2006,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2006
STD-traditional---Xu-2004,Acupuncture for schizophrenia,High risk,Sham electroacupuncture not used.,2004
STD-traditional---Zhao-2005a,Acupuncture for schizophrenia,High risk,Used placebo but did not use sham acupuncture.,2005
STD-traditional---Zhao-2005b,Acupuncture for schizophrenia,High risk,Used placebo but did not use sham acupuncture.,2005
STD-Henderson-2004-a,Advance treatment directives for people with severe mental illness,Low risk,One investigator collected follow-up data and was blinded to treatment group. Double-blinding not possible due to nature of intervention.,2004
STD-Papageorgiou-2002,Advance treatment directives for people with severe mental illness,High risk,"It was impossible to mask the research assistants to the patients' allocation as they were required to assist patients to make a directive in those allocated to the intervention group. However[comma] systematic bias was unlikely as the primary outcome concerned compulsory hospital admission and was not based on any later assessment by the researcher." Bias possible for secondary outcome measures.,2002
STD-Boyer-1995,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1995
STD-Carrière-2000,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Colonna-2000,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Costa-e-Silva-1989,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1989
STD-Danion-1999,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1999
STD-Delcker-1990,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1990
STD-Klein-1985,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1985
STD-Loo-1997,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Möller-1997,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Paillère-Martinot-95,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1995
STD-Peuskens-1999,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1999
STD-Pichot-1988a,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1988
STD-Pichot-1988b,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1988
STD-Puech-1998,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1998
STD-Rüther-1988,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1988
STD-Saletu-1994,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1994
STD-Speller-1997,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Wetzel-1998,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1998
STD-Ziegler-1989,Amisulpride for schizophrenia,Information could not be retrieved,Information could not be retrieved,1989
STD-Bai-2005,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Single[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side effects. This can be a problem for blinding.,2005
STD-Hwang-2003,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] identical capsules. Whether blinding was successful has not been examined[comma] but both compounds differ in side effects. This may be a problem for blinding.,2003
STD-Lecrubier-2006,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side effects. This can be a problem for blinding.,2006
STD-Mortimer-2004,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] identical capsules ("to permit dose adjustment whilst maintaining the double-blind[comma] blister packs corresponding to a low and a high dosage were provided"). Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side effects. This can be a problem for blinding.,2005
STD-Möller-2005,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ in side effects. This may be a problem for blinding.,2004
STD-Olie-2006,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side effects. This can be a problem for blinding.,2006
STD-Peuskens-1999,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] identical capsules. Whether blinding was successful has not been examined[comma] but both compounds in side effects. This may be a problem for blinding.,1999
STD-Sechter-2002,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ in side effects. This may be a problem for blinding.,2002
STD-Vanelle-2006,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side effects. This can be a problem for blinding.,2006
STD-Wagner-2005,Amisulpride versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in side effects. This can be a problem for blinding.,2005
STD-Mathew-1989,Amphetamines for schizophrenia,Information could not be retrieved,Information could not be retrieved,1989
STD-Modell-1965,Amphetamines for schizophrenia,Information could not be retrieved,Information could not be retrieved,1965
STD-Wolkin-1987,Amphetamines for schizophrenia,Information could not be retrieved,Information could not be retrieved,1987
STD-Wolkin-1994,Amphetamines for schizophrenia,Information could not be retrieved,Information could not be retrieved,1994
STD-Bucci-1971,Anticholinergic medication for antipsychotic-induced tardive dyskinesia,High risk,Blinding of participants and personnel not reported.,1971
STD-Greil-1984,Anticholinergic medication for antipsychotic-induced tardive dyskinesia,Low risk,"double-blind" "investigators were not informed about the study design".,1984
STD-Becker-1983,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1983
STD-Dufresne-1988,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1988
STD-Hogarty-1995,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1995
STD-Jasovic-1996,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1996
STD-Johnson-1981,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1981
STD-Kramer-1989,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1989
STD-Kurland-1981,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1981
STD-Mulholland-1997,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1997
STD-Prusoff-1979,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1979
STD-Singh-1978,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1978
STD-Siris-1987,Antidepressants for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1987
STD-Collins-1967,Antidepressants for the negative symptoms of schizophrenia,Information could not be retrieved,Information could not be retrieved,1967
STD-Hayashi-1997,Antidepressants for the negative symptoms of schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Jockers-2005,Antidepressants for the negative symptoms of schizophrenia,Information could not be retrieved,Information could not be retrieved,2005
STD-Silver-1992,Antidepressants for the negative symptoms of schizophrenia,Information could not be retrieved,Information could not be retrieved,1992
STD-Spina-1994,Antidepressants for the negative symptoms of schizophrenia,Information could not be retrieved,Information could not be retrieved,1994
STD-Belanoff-2001,Antiglucocorticoid and related treatments for psychosis,Low risk,"..patients served as their own controls in a random-assignment[comma] double-blind crossover design" (pg 517).,2001
STD-DeBattista-2006,Antiglucocorticoid and related treatments for psychosis,Low risk,Quote: "randomised 1:1 to 7 days of inpatient treatment in a double-blind[comma] placebo controlled[comma] parallel group design" (pg 1344).,2006
STD-Flores-2006,Antiglucocorticoid and related treatments for psychosis,Low risk,Quote: "Patients were randomised to either 600mg per day of double-blind mifepristone or placebo for eight days" (pg 630).,2006
STD-Gallagher-2005,Antiglucocorticoid and related treatments for psychosis,Low risk,"Administration of medication was in a double-blind design" (pg 156). Outcome assessors were blind (source: correspondence).,2005
STD-Marco-2002,Antiglucocorticoid and related treatments for psychosis,Low risk,Participant/providers: Yes. Quote: "Subjects were randomised to receive in a double-blind manner..." (pg 157). Outcome assessors: Yes. Quote: "Subjects and blinded raters were not able to accurately guess treatment assignment based on side effects." (pg 159).,2002
STD-Nachshoni-2005,Antiglucocorticoid and related treatments for psychosis,Low risk,Participant/providers: Yes. Quote: "...randomised to receive either DHEA at a fixed dose of 100 mg/day or placebo in double-blind fashion..." (pg 252). Outcome assessors blind (from correspondence).,2005
STD-Newcomer-1998,Antiglucocorticoid and related treatments for psychosis,Low risk,Quote: "...after 4 days of double-blind[comma] placebo controlled treatment with DEX..." (pg 67).,1998
STD-Ritsner-2006,Antiglucocorticoid and related treatments for psychosis,Low risk,Participant/providers: participants[comma] providers and key study personnel blinded (source: correspondence). Outcome assessors: yes (from correspondence).,2006
STD-Ritsner-2010,Antiglucocorticoid and related treatments for psychosis,Low risk,"Double-blind study design" (pg 1352).,2010
STD-Strous-2003,Antiglucocorticoid and related treatments for psychosis,Low risk,Participant/providers: yes. Quote: "..to receive either DHEA or placebo[comma] each for six weeks in a double-blind manner (administered and monitored by a hospital pharmacist)" (pg 134). Outcome assessors blinded (Source: correspondence).,2003
STD-Strous-2007,Antiglucocorticoid and related treatments for psychosis,Low risk,Participant/providers: Yes. Quote: "...to receive either DHEA or placebo[comma] each for 12 weeks in a double-blind manner" (pg 97). Outcome assessors blinded (source: correspondence).,2007
STD-Adler-1993a,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,1993
STD-Adler-1999,Antioxidant treatments for schizophrenia,Low risk,Double-blind[comma] no further details.,1999
STD-Akhondzadeh-2005,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2005
STD-Amiri-2008,Antioxidant treatments for schizophrenia,Low risk,Identical tablets.,2008
STD-Berk-2008b,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2008
STD-Bodkin-2005,Antioxidant treatments for schizophrenia,Low risk,"drug and placebo in matched capsules".,2005
STD-Bordbar-2008,Antioxidant treatments for schizophrenia,Low risk,"Identical placebo".,2008
STD-Brunstein-2005,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2005
STD-Dakhale-2005,Antioxidant treatments for schizophrenia,Low risk,Medicines identical in formulation.,2005
STD-Dickerson-2009,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2009
STD-Dorevitch-1997a,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,1997
STD-Doruk-2008,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2008
STD-Farokhnia-2013,Antioxidant treatments for schizophrenia,Low risk,"identical containers".,2013
STD-Goff-1993,Antioxidant treatments for schizophrenia,Low risk,Identical capsules given.,1993
STD-Jungerman-1999,Antioxidant treatments for schizophrenia,Low risk,"Identical appearance".,1999
STD-Lohr-1996,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,1996
STD-Luo-1997,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,1997
STD-Ritsner-2010,Antioxidant treatments for schizophrenia,Low risk,"identical capsules".,2010
STD-Weiser-2012,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2012
STD-Zhang-2001a,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2001
STD-Zhang-2004,Antioxidant treatments for schizophrenia,Low risk,Double-blind.,2004
STD-Zhang-2011,Antioxidant treatments for schizophrenia,Low risk,"Identically appearing placebo".,2011
STD-A-+any-antipsychotic-2011,Antipsychotic combinations for schizophrenia,High risk,Open-label[comma] participants and personnel were not blinded[comma] Assessment by blinded clinical raters[comma] precautions were taken not to reveal treatment allocation to raters.,2011
STD-A-+any-antipsychotic-2012,Antipsychotic combinations for schizophrenia,High risk,“Choice of medication to join was left to prescriber and patient  and also at their discretion the dose of all drug could be raised or lowered .” “Outcomes were performed by trained assessor masked to allocated treatment.”.,2012
STD-A-+any-antipsychotic-2015,Antipsychotic combinations for schizophrenia,High risk,“While treatment was open-label[comma] baseline and subsequent assessments were conducted by “independent assessors” blinded to the research status of participants.”.,2015
STD-A-+pimozide-1985,Antipsychotic combinations for schizophrenia,Low risk,Drug appearance[comma] with respect to powder colour[comma] taste[comma] and volume[comma] was made identical by adding a common gastric aid[comma] SMP.,1985
STD-A-+reserpine-1957,Antipsychotic combinations for schizophrenia,Low risk,Neither raters nor participants were aware of the nature or quantity of drug given. Participants were given an identical number of capsules regardless of the individual dosage.,1957
STD-A-+sulpiride-1994,Antipsychotic combinations for schizophrenia,High risk,Open-label study.,1994
STD-A-+trifluoperazine-1964,Antipsychotic combinations for schizophrenia,Low risk,Placebo capsules and placebo tablets matched the appearance of the capsules and tablets of the two drugs to insure no knowledge of which group was receiving which drug or drugs.,1964
STD-B-+any-antipsychotic-2013,Antipsychotic combinations for schizophrenia,High risk,“For participants who were assigned to switch to monotherapy[comma] each participant and physician decided together which of the two anti- psychotics to discontinue.”   “The raters were blinded about which group the patients belonged to.”.,2013
STD-B-+aripiprazole-2008,Antipsychotic combinations for schizophrenia,Unclear Risk,"Double-blind"[comma] no further details reported.,2008
STD-B-+aripiprazole-2011,Antipsychotic combinations for schizophrenia,Low risk,Aripiprazole and placebo were dispensed in identical-appearing capsules; patients randomise to placebo took the same number of capsules as those assigned to aripiprazole.,2011
STD-B-+pipotiazine-2002,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2002
STD-B-+quet/risp-2009,Antipsychotic combinations for schizophrenia,Unclear Risk,No details provided.,2009
STD-B-+risperidone-2010,Antipsychotic combinations for schizophrenia,Unclear Risk,"Double-blind"[comma] no further details provided for blinding of participants and personnel[comma] raters were blinded to treatment assignment.,2010
STD-B-+sulpiride-1996,Antipsychotic combinations for schizophrenia,Unclear Risk,Not described. Unclear if outcome assessment was blinded.,1996
STD-B-+ziprasidone-2014,Antipsychotic combinations for schizophrenia,Unclear Risk,“None of the research personnel[comma] who enrolled[comma] assessed[comma] and treated the patients[comma] were aware of the patient assignments until the study was concluded. Ziprasidone and placebo were dispensed in identical-appearing capsules; patients randomized to placebo took the same number of capsules as those assigned to ziprasidone.”.,2014
STD-C-+amisulpride-2008,Antipsychotic combinations for schizophrenia,Unclear Risk,No details provided.,2008
STD-C-+arip/pali-2014,Antipsychotic combinations for schizophrenia,Low risk,“Double blinding was done by inserting aripiprazole or paliperidone or placebo tablet in a non-transparent capsule.” “It was handed over along with identical plastic containers filled with the study drugs (45 capsules each of aripiprazole or paliperidone or placebo) to a third person not directly involved in this study.” “The patient as well as the investigator was unaware of the treatment being administered.”.,2014
STD-C-+aripiprazole-2007,Antipsychotic combinations for schizophrenia,Unclear Risk,Not reported.,2007
STD-C-+aripiprazole-2007b,Antipsychotic combinations for schizophrenia,Unclear Risk,No details provided.,2007
STD-C-+aripiprazole-2008,Antipsychotic combinations for schizophrenia,Low risk,All the participants and investigators remained blind throughout the study[comma] and the data analyses were also performed by investigators blind to the identity of the participants.,2008
STD-C-+aripiprazole-2008b,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2008
STD-C-+aripiprazole-2009,Antipsychotic combinations for schizophrenia,Unclear Risk,Single-blind[comma] untested.,2009
STD-C-+aripiprazole-2012,Antipsychotic combinations for schizophrenia,Unclear Risk,"Patients were evaluated by the same investigator. This investigator was from a different hospital and was not involved in patient care. In addition[comma] the investigator was blind to drug regimens and the drug concentrations. However[comma] he had access to the nursing charts." No details as to blindness of participants and personnel other than "double-blind".,2012
STD-C-+aripiprazole-2013,Antipsychotic combinations for schizophrenia,Unclear Risk,“Double blind” No other information provided.,2013
STD-C-+aripiprazole-2013b,Antipsychotic combinations for schizophrenia,Unclear Risk,“Double-blind”. No further details.,2013
STD-C-+aripiprazole-2014,Antipsychotic combinations for schizophrenia,Low risk,Double blind. Placebo[comma] which have the same colour[comma] shape and taste with aripiprazole.,2014
STD-C-+aripiprazole-2015,Antipsychotic combinations for schizophrenia,Low risk,"Double-blind”  "Placebo and aripiprazole tablets were physically indistinguishable.",2015
STD-C-+aripiprazole-2015b,Antipsychotic combinations for schizophrenia,Low risk,“placebo tablets that were identical to the aripiprazole tablets...” AND “The investigators[comma] participants and their carers were masked to the medications throughout the study...”.,2015
STD-C-+aripiprazole-2015c,Antipsychotic combinations for schizophrenia,High risk,“Open-label trial”.,2015
STD-C-+aripiprazole-2016,Antipsychotic combinations for schizophrenia,High risk,Open-label trial.,2014
STD-C-+clozapine-2001,Antipsychotic combinations for schizophrenia,Unclear Risk,No information provided.,2001
STD-C-+clozapine-2013,Antipsychotic combinations for schizophrenia,High risk,Not specified.,2013
STD-C-+CPZ-1973,Antipsychotic combinations for schizophrenia,Unclear Risk,At both centres[comma] all patients involved in the study had their dosage regulated by the usual clinical staff. The research psychiatrist at each centre scrupulously avoided influencing the amount or frequency of administration of antipsychotic medication used during the course of the study[comma] except to specify that fluphenazine enanthate dosage should not exceed 75 mg in a single dose.,1973
STD-C-+CPZ-1989,Antipsychotic combinations for schizophrenia,Unclear Risk,Weekly BPRS by psychiatrists blind to medication over 8 weeks. No further details.,1989
STD-C-+CPZ-1999,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,1999
STD-C-+fluphen-dec-2009,Antipsychotic combinations for schizophrenia,Low risk,"Double-blind". "The placebo had been arranged in the shape of comparable vials[comma] like the target drug". "The evaluators[comma] as well[comma] were unaware concerning the partition and the type of medications arranged for each group.",2009
STD-C-+haloperidol-2006,Antipsychotic combinations for schizophrenia,Unclear Risk,"Double-blind" no further details reported.,2006
STD-C-+haloperidol-2010,Antipsychotic combinations for schizophrenia,Unclear Risk,Double-blind[comma] no further details.,2010
STD-C-+levomepromazine 2004,Antipsychotic combinations for schizophrenia,High risk,Open-label trial.,2004
STD-C-+olan/risp-2014,Antipsychotic combinations for schizophrenia,High risk,Rater-blinded. Participants where not blinded to the intervention.,2014
STD-C-+olanzapine-2012,Antipsychotic combinations for schizophrenia,High risk,Participants and personnel were not blinded. Blind outcome assessment "Rater blinded".,2012
STD-C-+olanzapine-2012b,Antipsychotic combinations for schizophrenia,Low risk,Double blind: “Olanzapine and placebo were dispensed in similar gelatin capsules that were formulated for this trial.” “The rater was blind to the study medication (i.e.[comma] either olanzapine or placebo) until the completion of the trial in each case.”.,2012
STD-C-+perphenazine-1976,Antipsychotic combinations for schizophrenia,Low risk,Identical tablets were used for active drugs and placebo.,1976
STD-C-+pimozide-2011,Antipsychotic combinations for schizophrenia,Unclear Risk,Double-blind[comma] "Given that the increased risk of extrapyramidal symptoms associated with pimozide threatened the integrity of the blind[comma] assignment of assessments ensured that the rating of the ESRS was carried out by personnel different from those performing the PANSS and functional competence ratings.",2011
STD-C-+pimozide-2013,Antipsychotic combinations for schizophrenia,Low risk,Double-blind: “Patients were randomized to identical looking pimozide or placebo capsules by the research pharmacist who was not involved with the subjects.”.,2006
STD-C-+pipotiazine-2000,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2000
STD-C-+risperidone-2001,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2001
STD-C-+risperidone-2001b,Antipsychotic combinations for schizophrenia,Unclear Risk,No information provided.,2001
STD-C-+risperidone-2001c,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2001
STD-C-+risperidone-2005,Antipsychotic combinations for schizophrenia,Low risk,Identical pills containing either risperidone or placebo were added to clozapine.,2005
STD-C-+risperidone-2005b,Antipsychotic combinations for schizophrenia,Low risk,The raters[comma] treating psychiatrist[comma] and patient remained blinded throughout the study.,2005
STD-C-+risperidone-2006,Antipsychotic combinations for schizophrenia,Low risk,Throughout the study[comma] the patients[comma] sight investigators[comma] and raters remained blinded.,2006
STD-C-+risperidone 2007,Antipsychotic combinations for schizophrenia,Low risk,An independent research pharmacy prepared matching capsules that contained either 1 mg risperidone or placebo.,2007
STD-C-+sertindole-2006,Antipsychotic combinations for schizophrenia,Low risk,Participants[comma] personnel and assessors were blinded[comma] "Blinding was concealed until the end of the 12-week visit[comma] and disclosure of the blinding was first done after reporting all PANSS values to the pharmacy to ensure that the primary outcome data could not be changed after unblinding". Blinded raters performed all clinical research assessments.,2006
STD-C-+sulpiride-1997,Antipsychotic combinations for schizophrenia,Low risk,The placebo tablets were made to appear identical to the sulpiride tablets by the manufacturer.,1997
STD-C-+sulpiride-1999,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,1999
STD-C-+sulpiride-1999b,Antipsychotic combinations for schizophrenia,Unclear Risk,Double-blind.,1999
STD-C-+sulpiride-1999c,Antipsychotic combinations for schizophrenia,Unclear Risk,No information provided.,1999
STD-C-+sulpiride-2003,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2003
STD-C-+sulpiride-2004,Antipsychotic combinations for schizophrenia,High risk,Limitations for the study include the absence of a double-blind[comma] placebo-controlled study design[comma] and non-blind rating.,2004
STD-C-+sulpiride-2006,Antipsychotic combinations for schizophrenia,Unclear Risk,Not stated.,2006
STD-C-+sulpiride-2013,Antipsychotic combinations for schizophrenia,Unclear Risk,“Double blind”. No other information provided.,2013
STD-Huang-2007,Antipsychotic drug treatment for elderly people with late-onset schizophrenia,High risk,There was no blinding.,2007
STD-Engelhardt-1973,Antipsychotic medication for childhood-onset schizophrenia,Information could not be retrieved,Information could not be retrieved,1973
STD-Faretra-1970,Antipsychotic medication for childhood-onset schizophrenia,Information could not be retrieved,Information could not be retrieved,1970
STD-Kumra-1996,Antipsychotic medication for childhood-onset schizophrenia,Information could not be retrieved,Information could not be retrieved,1996
STD-Shaw-2006,Antipsychotic medication for childhood-onset schizophrenia,Information could not be retrieved,Information could not be retrieved,2006
STD-Xiong-2004,Antipsychotic medication for childhood-onset schizophrenia,Information could not be retrieved,Information could not be retrieved,2004
STD-Yao-2003,Antipsychotic medication for childhood-onset schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Cole-1964,Antipsychotic medication for early episode schizophrenia,Unclear Risk,Double blind[comma] untested.,1964
STD-May-1976,Antipsychotic medication for early episode schizophrenia,High risk,Open study.,1965
STD-Mosher-1995,Antipsychotic medication for early episode schizophrenia,High risk,Treated at different sites.,1995
STD-Rappaport-1978,Antipsychotic medication for early episode schizophrenia,Low risk,Reported that "staff remain blind to whether the patient was receiving medication or placebo".,1978
STD-Simon-1965,Antipsychotic medication for early episode schizophrenia,Unclear Risk,No details.,1959
STD-Harvey/Jeste-2003,Antipsychotic medication for elderly people with schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Phanjoo-1990,Antipsychotic medication for elderly people with schizophrenia,Information could not be retrieved,Information could not be retrieved,1990
STD-Tollefson-1997,Antipsychotic medication for elderly people with schizophrenia,Information could not be retrieved,Information could not be retrieved,1997
STD-Bai-2003,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Low risk,"double-blind" "A placebo with an identical appearance to the risperidone dose was prescribed for the placebo group using the same dose schedule.",2003
STD-Bai-2005,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,High risk,"single-blind and controlled study".,2005
STD-Caroff-2011,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Low risk,"...double-blind conditions..." "Identical-appearing capsules contained olanzapine (7.5 mg)[comma] quetiapine (200 mg)[comma] risperidone (1.5 mg)[comma] perphenazine (8 mg)[comma] or ziprasidone (40 mg).",2011
STD-Chan-2010,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,High risk,"...primary care physicians and patients were not blinded.",2010
STD-Chouinard-1995,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Low risk,"identical tablets".,1995
STD-Cookson-1987,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Unclear Risk,"double blind"[comma] no further details.,1987
STD-Emsley-2004,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,High risk,"investigator-blinded"[comma] further blinding details not reported.,2004
STD-Glazer-1990a,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Low risk,"double blind" "Medication was supplied in identical-appearing red capsules containing 25 mg and 5 mg[comma] respectively[comma] of molindone and haloperidol".,1990
STD-Kane-1983,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Unclear Risk,"double-blind". Details not reported.,1983
STD-Kazamatsuri-1972,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Unclear Risk,Blinding of participants not reported. Ward nurses were blinded.,1972
STD-Kazamatsuri-1973,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,High risk,Blinding of participants and personnel not reported.,1973
STD-Lublin-1991,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,High risk,Blinding of participants and personnel not reported.,1991
STD-Tamminga-1994,Antipsychotic reduction and or cessation and antipsychotics as specific treatments for tardive dyskinesia,Unclear Risk,"Staff[comma] patients[comma] and all raters were blind to the drug group; one non rating physician and one nurse were non blind to dispense medication and monitor safety"; no further details were provided.,1994
STD-Casey-2003,Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems,Low risk,Quote: "Open label".  Comment: lack of blinding is less prone to cause bias for outcomes like weight. Lack of blinding may introduce bias for subjective outcomes like adverse events.,2003
STD-Cookson-1986,Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems,Low risk,Quote:" double blind"  Comment: the methods used if any to ensure participants and trialists were blind to the interventions used are not described. We feel as the primary outcome is objective (weight) inadequate blinding is unlikely to cause bias.,1986
STD-Eli-Lilly-2004,Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems,Low risk,Quote: "double blind". Comment: the methods used if any to ensure participants and trialists were blind to the interventions used are not reported[comma] but both the intervention medication and the control were in capsule forms. We feel inadequate blinding is not likely to introduce bias for objective outcomes like weight BMI and metabolic syndrome.,2004
STD-Newcomer-2008,Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems,Low risk,Quote:"double blind study". Comment: methods taken to ensure blindness not reported. For outcomes like weight[comma] BMI[comma] waist circumference and metabolic syndrome[comma] inadequate blinding is unlikely to cause bias.,2007
STD-Andrezina-2006,Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation),Unclear Risk,Described as double-blind[comma] no further details given.,2006
STD-Bristol-Myers-2005,Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation),Unclear Risk,No blinding was used during the preparation of injections; in most cases the same person prepared and administered the drug. Study investigators conducting the assessment were blinded to treatment.,2005
STD-Kittipeerachon-2016,Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation),Low risk,"The patients and the physician investigator were blinded to treatment assignment as long as the 24-hour assessment was not completed. The assessment was performed by the investigator and the nurse who administered the injection was not involved in the assessment process of the study." (p.232).,2016
STD-Adson-2003,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Carson-2000-a,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Carson-2002-b,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2002
STD-Csernansky-2003,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Daniel-2000,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Daniel-2004,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2004
STD-Kane-2003,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Kern-2001,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2001
STD-Kujawa-2002,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2002
STD-Marcus-2005,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2005
STD-McQuade-2003,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Oren-2005,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2005
STD-Potkin-2003,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Riera-2004,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2004
STD-Stock-2005,Aripiprazole for schizophrenia,Information could not be retrieved,Information could not be retrieved,2005
STD-An-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Bai-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Unclear.,2007
STD-Bai-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Ban-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Chan-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] identical capsules. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in adverse effects. This can be a problem for blinding.,2007
STD-Chang-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Chen-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Chen-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Chen-2008a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Chen-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,High risk,Open label.,2009
STD-Chen-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Chen-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Low riskUnclear riskHigh risk.,2010
STD-Chen-2010a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Cheng-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-CuiMeng-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Dai-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Dai-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Deng-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Deng-2008a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Ding-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Du-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Fan-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Fan-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Feng-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Fleischhacker-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in adverse effects. This can be a problem for blinding.,2005
STD-Fu-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Ge-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Ge-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Guo-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double.,2006
STD-Han-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Han-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Han-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Hu-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Huang-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Ji-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Jiang-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Jie-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Kane-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,No details.,2009
STD-Kern-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,High risk,Open label.,2006
STD-Kerwin-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,High risk,Open label.,2007
STD-Kinon-2004,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double. No further details available.,2004
STD-Kuang-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006[comma] 2006
STD-Li-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Li-2006a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Li-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Li-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Li-2007b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Li-2007c,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Li-2007d,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Li-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Li-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Li-2009b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Li-X-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Lian-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Liang-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Liu-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Liu-2006a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Liu-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Liu-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Liu-2008a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Liu-2008b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Liu-2008c,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Liu-2008d,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Liu-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Liu-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Liu-2009b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Liu-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Lou-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Luo-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Luo-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Lv-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Ma-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Ma-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Mai-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Mao-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-McQuade-2004,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] no further details. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in adverse effects. This can be a problem for blinding.,2004
STD-Mu-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Mu-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Pan-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Peng-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Peng-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Potkin-2003,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double[comma] identical capsules. Whether blinding was successful has not been examined[comma] but both compounds differ quite substantially in adverse effects. This can be a problem for blinding.,2003
STD-Pu-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Qian-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Qin-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Qu-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Shan-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Shuai-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Song-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Song-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Song-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Su-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Su-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Sun-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Sun-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Sun-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Tandon-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,High risk,Open label.,2006
STD-Tang-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Tang-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Tang-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Tang-2010a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Tao-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Tong-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Tu-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Wang-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Wang-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Wang-2006a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Wang-2006b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Wang-2006c,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Wang-2006d,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Wang-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Wang-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Wang-2007d,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Wang-2007e,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Wang-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Wang-2008c,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Wang-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Wei-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Wei-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Wei-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Wen-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Wen-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Wlodzmierz-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,High risk,Open label.,2006
STD-Wolf-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,High risk,Open label.,2007
STD-Wu-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Xiao-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Xie-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Xie-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Xu-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Xu-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Low risk,Double.,2010
STD-Yan-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Double.,2007
STD-Yan-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Yan-2008a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Yan-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Yang-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not stated.,2006
STD-Yang-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Yang-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Yang-2008a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Yang-2008b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Yang-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Ye-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Ye-2005a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Yi-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Yu-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Yu-2006a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Yu-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Yu-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Yu-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Yu-ZG-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhang-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Zhang-2006a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Zhang-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhang-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhang-2007b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhang-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Zhang-2008a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Zhang-2008b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Zhang-2009,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Zhang-2009a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Single[comma] if the blinding was performed well was unknown.,2009
STD-Zhang-2009b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2009
STD-Zhang-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Zhang-2010a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Zhao-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not described.,2006
STD-Zhao-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhi-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2005
STD-Zhou-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhou-2007a,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhou-2007b,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2007
STD-Zhou-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Zhu-2005,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Single blind[comma] but whether the blindness was performed well was unclear.,2005
STD-Zhu-2008,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2008
STD-Zhu-2010,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2010
STD-Zimbroff-2007,Aripiprazole versus other atypical antipsychotics for schizophrenia,Low risk,Double[comma] double dummy administration. Whether blinding was successful has not been examined[comma] but both compounds have similar adverse effects.,2007
STD-Zou-2006,Aripiprazole versus other atypical antipsychotics for schizophrenia,Unclear Risk,Not reported.,2006
STD-Adson-2003,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double blind[comma] no further details.,2003
STD-Carson-2000-a,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double blind[comma] method of blinding not described.,2000
STD-Carson-2002-b,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double[comma] no further details.,2002
STD-Csernansky-2003,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double[comma] no further details.,2003
STD-Daniel-2000,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Unclear.,2000
STD-Daniel-2004,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double[comma] no further details.,2004
STD-Marcus-2005,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double[comma] no further details.,2005
STD-Oren-2005,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double[comma] no further details.,2005
STD-Potkin-2003,Aripiprazole versus placebo for schizophrenia,Unclear Risk,Double[comma] no further details.,2003
STD-Carson-2000,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Csernansky-2003,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Daniel-2000,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2000
STD-Daniel-2004,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2004
STD-Kane-2003,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2003
STD-Kujawa-2002,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2002
STD-McCue-2006,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2006
STD-Oren-2005,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2005
STD-Wang-2005,Aripiprazole versus typical antipsychotic drugs for schizophrenia,Information could not be retrieved,Information could not be retrieved,2005
STD-Green-1987,Art therapy for schizophrenia or schizophrenia-like illnesses,Information could not be retrieved,Information could not be retrieved,1987
STD-Richardson-2002,Art therapy for schizophrenia or schizophrenia-like illnesses,Information could not be retrieved,Information could not be retrieved,2000
STD-Chapel-2009,Asenapine versus placebo for schizophrenia,Unclear Risk,"Double-blind" - but no further description provided.,2009
STD-Kane-2010,Asenapine versus placebo for schizophrenia,Unclear Risk,"Double-blind" - but no further description provided.,2010
STD-Kane-2011,Asenapine versus placebo for schizophrenia,Low risk,"Double-blind". "asenapine and placebo sublingual tablets were identical in appearance". "neither patients nor sites were aware of the tablet identity". Probably done.,2011
STD-NCT00151424,Asenapine versus placebo for schizophrenia,Unclear Risk,Double-blind - no further description.,2005
STD-NCT00156117,Asenapine versus placebo for schizophrenia,Unclear Risk,"Double-Blind (subject[comma] caregiver[comma] investigator[comma] outcomes assessor)". No further description.,2005
STD-Potkin-2007,Asenapine versus placebo for schizophrenia,Low risk,"Double-blind" "In this double-dummy design[comma] asenapine-treated patients also received oral placebo BID...and patients in the placebo-control group received oral and sublingual placebo BID". Probably done.,2007
STD-Alfredsson-1984,Atypical antipsychotics for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1984
STD-Emsley-2003,Atypical antipsychotics for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,2003
STD-Jasovic-1997,Atypical antipsychotics for people with both schizophrenia and depression,Information could not be retrieved,Information could not be retrieved,1997
STD-Aranda-2007,Atypical antipsychotics for psychosis in adolescents,High risk,This was an open-label study.,2007
STD-DelBello-2008,Atypical antipsychotics for psychosis in adolescents,High risk,This was an open-label trial.,2006
STD-Findling-2008,Atypical antipsychotics for psychosis in adolescents,Low risk,This was a double-blind placebo-controlled trial.,2008
STD-Haas-2009,Atypical antipsychotics for psychosis in adolescents,Low risk,This was a double-blind study.,2009
STD-Huo-2007,Atypical antipsychotics for psychosis in adolescents,Unclear Risk,Not described in the report.,2007
STD-Jensen-2008,Atypical antipsychotics for psychosis in adolescents,High risk,This was an open-label study.,2007
STD-Kryzhanovskaya-2009,Atypical antipsychotics for psychosis in adolescents,Low risk,There was a double-blind phase followed by an open-label phase.,2009
STD-Kumra-1996,Atypical antipsychotics for psychosis in adolescents,Low risk,Raters[comma] treating physicians and nurses were blind to the study status.,1996
STD-Kumra-2008,Atypical antipsychotics for psychosis in adolescents,Low risk,This was a double-blind RCT[comma] but the details of blinding and how it was maintained had not been described in the report.,2008
STD-Sikich-2004,Atypical antipsychotics for psychosis in adolescents,Low risk,This was a double-blind study[comma] but the details of how blinding was maintained were not reported.,2004
STD-Sikich-2008,Atypical antipsychotics for psychosis in adolescents,Low risk,This was a double-blind study[comma] and blinding was maintained even after discontinuation of one of the arms (olanzapine group) of the study for ethical reasons.,2008
STD-Swadi-2010,Atypical antipsychotics for psychosis in adolescents,High risk,Open-label study with blind midpoint and end point assessments.,2010
STD-Xiong-2004,Atypical antipsychotics for psychosis in adolescents,High risk,Blinding not clear.,2004
STD-Mahal-1976,Ayurvedic medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,1976
STD-Ramu-1992,Ayurvedic medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,1992
STD-Ramu-1999,Ayurvedic medicine for schizophrenia,Information could not be retrieved,Information could not be retrieved,1999
